Stem Cell Therapy in India for International Patients: Options, Evidence & 2026 Guide
Stem cell therapy generates more hope — and more confusion — than almost any other area of medicine. The term covers treatments ranging from genuinely curative bone marrow transplants with decades of evidence behind them to unproven injections sold on the basis of anecdote and marketing. For international patients investigating stem cell therapy in India, the essential distinction is between evidence-based, regulatory-approved applications and unproven commercial programmes. India has both. Only one category is worth travelling for.
TL;DR: Evidence-based stem cell therapies in India include BMT for blood cancers and thalassemia, CAR-T cell therapy (NexCAR19, approved 2023, USD 50,000–80,000), and autologous chondrocyte implantation for cartilage. Unproven stem cell clinics offering therapy for autism, cerebral palsy, or Parkinson's are not approved by CDSCO and should be avoided (ICMR Guidelines, 2023).
What Stem Cell Therapy Actually Means
"Stem cells" is not a single treatment — it's a broad category describing cells with the ability to self-renew and differentiate into specialised cell types. The clinical applications differ radically:
Haematopoietic stem cells (HSC): Blood-forming stem cells harvested from bone marrow, peripheral blood, or umbilical cord blood. When used in transplant, they reconstitute a patient's entire blood and immune system. This is the basis of bone marrow transplant (BMT) / haematopoietic stem cell transplant (HSCT).
CAR-T cells: T-lymphocytes (immune cells) genetically engineered to carry chimeric antigen receptors that recognise and kill specific cancer cells. A form of immunotherapy, not a traditional stem cell therapy, but developed from blood cell manipulation technology.
Mesenchymal stem cells (MSCs): Cells capable of differentiating into cartilage, bone, and fat. Used in autologous chondrocyte implantation for cartilage repair and under investigation for many other conditions.
Induced pluripotent stem cells (iPSCs): Laboratory-created cells reprogrammed to a pluripotent state. Currently in clinical trial phases for some conditions — not standard clinical practice.
Understanding which category a proposed therapy falls into is the first question to ask when evaluating any stem cell programme.
Evidence-Based Stem Cell Therapies in India
These treatments have regulatory approval, established protocols, and published outcome data:
Allogeneic Haematopoietic Stem Cell Transplant (BMT/HSCT)
The most established and proven stem cell therapy. Used for:
- Leukaemia (AML, ALL, CML, CLL) — curative in a significant proportion of cases
- Lymphoma (Hodgkin's, non-Hodgkin's) — for relapsed or high-risk cases
- Multiple myeloma — autologous SCT extends survival
- Aplastic anaemia — allogeneic SCT is curative
- Thalassemia major — curative in Class I/II patients with matched sibling donor
India performs thousands of BMTs annually at accredited centres. Costs range from USD 20,000–55,000 depending on donor type and indication — a fraction of equivalent programmes in the USA or Germany.
For detailed information on thalassemia BMT specifically, see our thalassemia treatment guide. For blood cancer BMT, see our blood cancer guide.
CAR-T Cell Therapy (NexCAR19)
India made international news in 2023 with the approval of NexCAR19 — the country's first indigenously developed CAR-T cell product, approved by the Central Drugs Standard Control Organisation (CDSCO) for:
- Relapsed or refractory B-cell lymphoma (large B-cell lymphoma)
- Relapsed or refractory B-cell ALL (acute lymphoblastic leukaemia)
How it works: The patient's own T-cells are collected via leukapheresis, sent to the manufacturing facility, genetically engineered to express CD19-targeting receptors (the antigen expressed on B-cells and their malignant counterparts), expanded, and reinfused. The CAR-T cells then hunt and destroy CD19-expressing cancer cells throughout the body.
Response rates for relapsed/refractory large B-cell lymphoma: In pivotal trials, 70–80% of patients achieve clinical response, with 40–50% achieving complete response — extraordinary results for a disease that otherwise has a poor prognosis.
Cost in India: USD 50,000–80,000 for the complete treatment cycle (leukapheresis, manufacturing, lymphodepletion conditioning, infusion, and 4–6 weeks monitoring). This is USD 400,000–500,000 in the USA, making India's programme genuinely transformative in access terms.
Currently available at: Tata Memorial Hospital (Mumbai), Christian Medical College (CMC) Vellore, Apollo Chennai, and a small number of other authorised academic centres.
Autologous Chondrocyte Implantation (ACI)
For patients with focal cartilage defects in the knee (not generalised osteoarthritis), ACI involves:
- Arthroscopic biopsy of healthy cartilage cells from a non-load-bearing area
- Laboratory culture to expand the chondrocyte population over 6–8 weeks
- Surgical implantation of cultured cells into the cartilage defect
ACI is a two-stage surgical procedure available at specialist orthopaedic centres in India for appropriately selected patients. Outcomes are best in younger patients with focal defects and intact surrounding cartilage.
What to Avoid: Unproven Stem Cell Clinics
India has a significant number of commercial clinics offering stem cell therapies for conditions where there is no credible evidence of benefit and no regulatory approval. The most commonly marketed unproven applications include:
- Autism spectrum disorder
- Cerebral palsy
- Parkinson's disease
- Spinal cord injury
- Motor neuron disease (ALS)
- Anti-ageing injections
- Diabetes treatment via stem cells
These programmes typically involve the injection of mesenchymal stem cells or other undefined cell preparations at high cost, with testimonials rather than trial data, and no follow-up data on outcomes or adverse events.
India's ICMR (Indian Council of Medical Research) guidelines and CDSCO explicitly prohibit the commercial use of unproven stem cell therapies outside of regulated clinical trials. These clinics operate in a regulatory grey area — many have been the subject of consumer complaints and regulatory action.
How to identify a legitimate programme:
- Has CDSCO approval for the specific indication
- Is performed at an NABH or JCI-accredited hospital
- Has peer-reviewed published data, not just testimonials
- Provides detailed informed consent covering specific risks of the procedure
- Has follow-up data and tracks outcomes
Arodya only refers patients to CDSCO-compliant programmes at accredited institutions. If you've been recommended a stem cell treatment by a commercial clinic and want an independent assessment of whether it's legitimate, contact us here — we'll tell you honestly what the evidence shows.
What to Bring for Stem Cell Therapy Evaluation
The documentation required depends on the condition:
For BMT/HSCT or CAR-T:
- Complete haematology workup (bone marrow biopsy with flow cytometry, cytogenetics, molecular markers)
- Previous treatment history (all prior chemotherapy regimens, responses, durations)
- HLA typing of patient and potential donors
- Current disease status (remission, relapse, partial response)
For cartilage repair (ACI):
- Knee MRI with cartilage-specific sequences
- Arthroscopy report if previous arthroscopy performed
- Symptom history and functional limitations
For a stem cell or BMT case review, submit your records to Arodya here. We'll have the appropriate specialist team evaluate your case and advise on whether a proven stem cell therapy is appropriate for your situation.
